CA-TIGO
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today unveiled a new set of powerful and customizable features of the Tigo Energy Intelligence (EI) Platform. With a newly retooled, upgraded, and tiered approach to delivering the right solar monitoring and insights, even small and mid-sized installation companies can manage their growing solar customer portfolios sustainably. These platform enhancements come online as the U.S. installed base of solar surpasses the 5 million solar installations threshold and the industry considers how it will manage the O&M work as those numbers double by 2030 and triple by 2034.
The Tigo EI Platform now offers upgrade options that deliver even more of the right information at the right time via a user-friendly interface to installers, asset managers, and down to the individual system owner. Most notably for rapidly scaling installers, EPCs, and O&M providers, the new EI Professional package provides a centralized view of critical health and performance data of all systems under management. Beyond a scalable monitoring experience and a simple, flat-price model, the EI Professional package includes:
- one-click enrollment for company-wide, unlimited-seat subscription access covering all systems under management,
- a portfolio-wide dashboard with a prioritized view into critical data, such as health status, production, performance, equipment status, location data, and commissioning time tracking, and
- time-saving features including advanced tagging, grouping, and site filtering for improved management, maintenance, optimization, and trend analysis.
Solar installers use the Tigo EI Platform to gain improved insights into installation status, decrease O&M costs, and monitor energy generation and system performance. The standard system-by-system monitoring view, now named EI Basic, remains free of charge, and includes module-level resolution and insight into third-party hardware. More advanced monitoring and analytics tools, historical data, and minute-level monitoring resolution, among others, are available via a simple, in-platform upgrade to EI Premium.
“As we watch the number, size, and complexity of the residential and commercial systems we deploy increase, we found that the only way to scale was with a comprehensive way to monitor, diagnose, and optimize those systems,” said Garrett Brandt, owner at Radius Energy. “When you consider the cost of even a single truck roll or the opportunity cost of a one-week delay in getting an invoice out post-commissioning, a paid subscription to avoid either makes sense right away. The features now available via the Tigo EI Platform don’t just add value in terms of savings but represent new opportunities for us on the installer side.”
Installer training materials for the EI Platform are now available in the Tigo Academy. Tigo Academy offers new and existing customers and installers an efficient way to learn about Tigo software through hands-on demonstrations and tutorials on how to leverage Tigo software for optimal system performance and customer satisfaction.
“To stay competitive, installers have to become more agile while providing more post-installation services, which is why Tigo has developed increasingly sophisticated options in the EI Platform that deliver the right management tools to the variety of customers we serve,” said Archie Roboostoff, vice president of software, at Tigo Energy. “Software plays an increasingly important role in ensuring that solar deployments reach peak performance while continuously analyzing trends to see where improvements can be made. The EI Platform is designed to identify system issues before production is impacted. System owners expect quality and reliability, and the EI Platform helps to deliver both.”
To learn more about the Tigo EI Platform, including the standard capabilities of EI Basic and the features and subscription pricing for EI Premium and EI Professional, please visit the EI features page at https://www.tigoenergy.com/ei/pricing. Tigo installers are also invited to take advantage of promotional trial access to EI Professional for the month of July, which is available via web browser on the Tigo EI Platform: https://ei.tigoenergy.com/
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709862359/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom